Last November, Ionis Pharmaceuticals announced their phase 3 trial for ION582, called REVEAL, an investigational ASO for the potential treatment of Angelman syndrome.
REVEAL is now listed on ClinicalTrials.gov. To learn more, join us at the community webinar hosted by ASF and FAST along with the Ionis team on Wednesday, April 23, 2025 at 1:00pm EST.
Submit your questions and register here.